HQ Team
July 15, 2025: Zimmer Biomet Holdings, Inc. will acquire Monogram Technologies Inc., an orthopaedic robotics company, for $177 million to expand its robotics portfolio.
Zimmer will buy all outstanding shares of Monogram for an upfront payment of $4.04 per share in cash, corresponding to an equity value of about $177 million, according to a statement.
Monogram shareholders will also receive a non-tradeable contingent value right entitling the holder to receive up to $12.37 per share of common stock in cash when certain product development, regulatory and revenue milestones are met through 2030.
Zimmer plans to fund the proposed transaction through a combination of cash and other available debt financing sources.
Robotic knee adoption
The acquisition expands Zimmer Biomet’s extensive suite of orthopaedic robotics, enabling solutions and analytics to address the needs of surgeons before, during and post-operations.
Zimmer Biomet stated that the planned acquisition was beneficial from both a strategic and financial standpoint. The acquisition of Monogram further strengthens Zimmer Biomet’s capabilities in robotics, one of the fastest-growing segments within orthopaedics.
Zimmer Biomet expects the acquisition will contribute to revenue growth in 2027 and beyond by improving the company’s robotic knee adoption in the US, increasing market share through reaching new customers with a broader product range, and expanding the company’s industry-leading global knee offerings.
Monogram’s semi-autonomous and fully autonomous robotic technologies are expected to expand Zimmer Biomet’s robotics platform and broad suite of navigation and enabling technologies.Â
Fully autonomous surgical robot
Monogram has developed an AI-navigated total knee arthroplasty robotic technology, which received FDA clearance in March 2025 and is expected to be commercialised with Zimmer Biomet implants in early 2027. Monogram is also developing a fully autonomous version of the technology.
After the deal closes, Zimmer Biomet “expects to have a clear pathway to become the first and only company in orthopaedics to offer a fully autonomous surgical robot.”
“Monogram’s technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation,” said Ivan Tornos, Chairman, President and Chief Executive Officer of Zimmer Biomet.
“Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons, now and into the future.”
